期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

大分割三维适形放疗联合吉西他滨治疗早期非小细胞肺癌 被引量：3

Three Dimensional Conformal Hypofractionated High Dose Radiotherapy Combined with Gemcitabine Concurrent Chemotherapy for Early-stage Non-Small-Cell Lung Cancer
下载PDF
导出
摘要 目的探讨大分割三维适形放疗(3DCRT)联合吉西他滨治疗早期非小细胞肺癌的疗效与不良反应。方法大剂量分割3DCRT治疗早期NSCLC28例,6～8Gy/次,隔日1次,3次/周,DT48～54Gy。并于放疗同期第1、8天给予吉西他滨600mg/m2。结果完全缓解率(CR)为39.3%,部分缓解率(PR)为60.7%,有效率(RR)为100%。1、2、3年总生存率为96.4%、78.6%和71.4%。结论大分割三维适形放疗联合吉西他滨治疗早期非小细胞肺癌有较好的疗效,可以改善生存,毒副反应可以耐受,是一种安全有效的治疗手段。 Objective To evaluate the efficacy and toxicity of three dimensional conformal hypofractionated high dose radiotherapy combined with Gemcitabine concurrent chemotherapy for early-stage non-small-cell lung cancer. Methods 28 cases patients with early-stage non-small-cell lung cancer were treated by three dimensional conformal hypofractionated high dose radiotherapy at the total dose of 48 to 54 Gy , 6 to 8 Gy for each fraction, 3 f/w. And they were also given Gemcitabine concurrent chemotherapy： Gemcitabine 600mg/m2, d1, 8. Results The complete remission rate was 39.3% and partial remission rate was 60.7%.The overall response rate was 100%. The 1-, 2-, 3-year survival rates were 96.4%, 78.6% and 71.4%. Conclusion Three dimensional conformal hypofractionated high dose radiotherapy combined with Gemcitabine concurrent chemotherapy for early-stage non-small-cell lung cancer is effective, the survival rate can be improved, the side effects are tolerable. It is one of safe and effective treatment.
作者 王瑜 韩俊庆
机构地区 山东大学附属山东省立医院肿瘤研究治疗中心
出处 《中国医药指南》 2010年第30期23-24,64,共3页 Guide of China Medicine
关键词 非小细胞肺癌 三维适形放疗 大分割放疗 化学疗法 Non-small-cell lung cancer Three dimensional conformal radiotherapy Hypofractionated radiotherapy Chemotherapy
分类号 R730.55 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Mountain GF.Revision in the intemational system for staging lung cancer[J].Chest,1997,111:1710-1717.
  • 2Cheung PCF,Markillop W J,Dixon P,et al.Involved-field radio-therapy alone for early-stage non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2000,48:703-710.
  • 3Martel MK,Ten-Haken RK,Hazuka MB,et al.Estimation of tumor control probability modrl param eters from 3-D dose distributions of non-small cell lung ancer patients[J].Lung Cancer,1999,24:31-37.
  • 4Das IJ,Cheng EC.Optimum beam angles for the conformal treatment of lung cancer:a CT simulation study[J].Int J Cancer,2000,90(6):359-365.
  • 5Wu KL,Jiang GL,Liao Y,et al.A phase Ⅰ study of gemcitabine with concurrent radiotherapy in stage Ⅲ,locally advanced nonsmall cell lung cancer[J].Cancer Res,2003,9(7):2472-2477.
  • 6Onishi H,Komiyama K,Komiyama T,et al.Clinical outcome of stereotactic radiotherapy for stage Ⅰ non-small cell lung cancer using a novel irradiation technique patirnt self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner[J].Lung Cancer,2004,45:45-55.
  • 7Nagata Y,Nagoro Y,Aoki T,et al.Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame[J].Int J Radiat Oncol Biol Phys,2002,52(4):1041-1046.
  • 8Kong FM,Ten Haken RK,Schipper M J,et al.High-dose radiation improed local tumor control and survival in patients with inoperable/unresectable non-small-cell lung cancer:long-term result of a radiation dose escalation study[J].Int J Radiat Oncol Biol Phys,2005,63(2):324-333.
  • 9Uematsu M,Shioda A,Taira J,et al.Computed Tomography (CT)-guided stereotactic radiation therapy (SRT) for stage Ⅰ non-small cell lung cancer (NSCLC):8-year results of 50 initial patients[J].Proc ASTRO 2003.Int J Radiat Oncol Biol Phys,2003,57(2):S281.
  • 10Hiroshi O,Yasushi N,Hiroki S,et al.Stereotactic hypofractionated high-dose irradiation for patients with stage Ⅰ non-small cell lung carcinoma clinical outcomes in 241 cases of a Japanese multi-institutional study[J].(Abstr) Int J Radiat Oncol Biol Phys,2003,57:124.

二级参考文献12

  • 1Seong J, Kim SH, Suh CO. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. J Gastroenterol Hepatol, 2001, 16: 883-889.
  • 2Shewach DS, Lawrence TS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol,1995,22: 68-71.
  • 3Stefania P, Franco M, Pamela P, et al. Effects of gemcitabine in normal and transformed human lung cell cultures: cytotoxicity and increase in radiation sensitivity. Tumori , 1999, 85:503-507.
  • 4van Bree C, Castro-Kreder N, Loves WJ, et al. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiat Oncol Biol Phys,2002,54:237-244.
  • 5Loprevite M, Favoni RE, de Cupis A, et al. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines.Lung Cancer,2001,33:27-39.
  • 6Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2', 2 '-Difluoro-2 '-deoxycytidine. Cancer Res,2000, 60: 6080-6088.
  • 7Gregoire V, Beauduin M, Bruniaux M, et al. Radiosensitization of mouse sarcoma cells by fludarabine( F-ara- A ) or gemcitabine( dFdC ), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsedfield gel electrophoresis. Int J Radiat Biol, 1998, 73:511-520.
  • 8Lawrence TS, Chang EY, Hahn TM, et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2', 2' -Difluoro-2' -deoxycytidine (gemcitabine). Clin Cancer Res, 1997, 6:777-782.
  • 9Latz D, Fleckenstein K, Eble M, et al. Radiosensitizing potential of gemcitabine(2', 2 '-Difluoro-2 '-deoxycytidine)within the cell cycle in vitro. Int J Radiat Oncol Biol Phys, 1998, 41: 875-882.
  • 10Rosier JF, Beauduin M, Bruniaux M, et al. The role of gemcitabineinduced cell cycle synchronization in radiosensitization of SCC61 human head and neck squamous carcinoma cell (HNSCC)line. Eur J Cancer,1997, 33: A89.

共引文献13

同被引文献18

中国医药指南
2010年 第30期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部